Dr. Kaushansky and colleagues propose to use a novel approach to identify ligand binding sites on the interleukin 3 (IL-3) receptor (IL-3R). The approach is to restore activity to a mutated IL 3 selecting for receptors bearing accommodating mutations. It is predicted that the nature and location of the mutation in the receptor will provide evidence for a direct interaction of that site with the altered site on the receptor mutant. To identify the receptor residues which bind to the site modified in a series of IL-3 loss-of-function muteins the PI will generate libraries of altered IL-3R a and bc subunits and utilize a selection method to identify reactivating modifications. The IL-3/IL-3Ra/bc interactions will then be modeled to generate further testable hypotheses. Dr. Kaushansky also proposes to use the recently developed technique of fluorescence resonance energy transfer (FRET) to dissect the sites at which the IL-3Ra and IL-3Rb subunits interact in the activated form of the receptor. Specifically, it is proposed to: 1.Determine whether the wild type residue altered in each of a series of loss-of-function human IL-3 muteins normally binds to the a or b chain of the IL-3 receptor. 2.Construct CDNA expression libraries containing multiple alterations of the IL-3 receptor a and b subunit sequences at a large number of sites, including those identified in other receptors to bind their corresponding ligands. 3.Screen the libraries for receptor clones, selecting for those that allow cellular proliferation in the presence of mutant IL-3 molecules that have otherwise lost activity on wild type IL-3 receptor-bearing cells.4.Model the interaction of IL-3 and its receptor, and test the model with additional IL-3 muteins and altered IL-3 receptor subunits.5.Determine the sites at which the IL-3Ra and bc subunits interact by site-specific mutagenesis, screening for receptor mutants that lose the capacity to heterodimerize based on the loss of energy transfer between fluorochrome-labeled monoclonal antibodies to each of the receptor subunits.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK043719-07
Application #
2905444
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Badman, David G
Project Start
1992-05-15
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Broudy, V C; Lin, N L; Sabath, D F (2001) The fifth immunoglobulin-like domain of the Kit receptor is required for proteolytic cleavage from the cell surface. Cytokine 15:188-95
Dahlen, D D; Lin, N L; Liu, Y C et al. (2001) Soluble Kit receptor blocks stem cell factor bioactivity in vitro. Leuk Res 25:413-21
Broudy, V C; Lin, N L; Liles, W C et al. (1999) Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 94:1979-86
Broudy, V C; Lin, N L; Buhring, H J et al. (1998) Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer. Blood 91:898-906
Kaushansky, K (1997) Thrombopoietin: platelets on demand? Ann Intern Med 126:731-3
Broudy, V C; Lin, N L; Kaushansky, K (1995) Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719-26
Kaushansky, K; Broudy, V C; Lin, N et al. (1995) Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A 92:3234-8
Drachman, J G; Griffin, J D; Kaushansky, K (1995) The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 270:4979-82
Kaushansky, K; Shoemaker, S G; O'Rork, C A et al. (1994) Coordinate regulation of multiple human lymphokine genes by Oct-1 and potentially novel 45 and 43 kDa polypeptides. J Immunol 152:1812-20
Kaushansky, K (1994) The mpl ligand: molecular and cellular biology of the critical regulator of megakaryocyte development. Stem Cells 12 Suppl 1:91-6;discussion 96-7

Showing the most recent 10 out of 11 publications